Evidence-Based Hair Growth Treatments (2025-2026)

Tier 1: FDA-Approved, Strongest Evidence

1. Topical Minoxidil

• Men: 5% topical solution or foam, applied twice daily
• Women: 2% topical solution (or 5% foam once daily)
• Mechanism: Prolongs the anagen (growth) phase, increases dermal papilla cell proliferation, increases hair caliber, and decreases follicular apoptosis. The active metabolite is minoxidil sulfate, produced by follicular sulfotransferase - individuals with low sulfotransferase activity may respond poorly.
• Evidence: Randomized controlled trials show increased hair density and thickness. Effects begin at 3-6 months and require continuous use; stopping causes acute telogen efflux 3-4 months later.
• Caution: Avoid in pregnancy and breastfeeding. Propylene glycol in older liquid formulations causes dermatitis in some users (foam formulation avoids this).
• Goldman-Cecil Medicine, p. 4334 | Dermatology 2-Volume Set 5e

2. Oral Finasteride (1 mg/day) - Men Only

• Mechanism: Selectively inhibits Type II 5α-reductase, blocking conversion of testosterone to dihydrotestosterone (DHT) in hair follicles. DHT is the key androgen that miniaturizes genetically susceptible follicles.
• Evidence: In a pivotal RCT of 1,553 men, finasteride significantly increased vertex hair counts vs. placebo at 1 year. 5-year data showed hair counts remained well above baseline in 90% of patients. Stabilized hair loss in 51% and produced regrowth in 48%. Hair growth peaks at 1-2 years.
• Works best in men with high DHT levels (e.g., mid-twenties). Also benefits frontal scalp, not just vertex.
• Side effects: Decreased libido (1.9%), erectile dysfunction (1.4%), decreased ejaculate (1.0%) - all resolve on drug cessation in most men. Rare: post-finasteride syndrome (persistent symptoms after stopping) - controversial but recognized.
• Key interactions: Lowers PSA by ~50% (inform urologist). Teratogenic to male fetuses - women must not handle crushed tablets.
• Topical finasteride spray is now available and as effective as oral, with less systemic DHT suppression.
• Cummings Otolaryngology, p. 2141 | Dermatology 2-Volume Set 5e | Rosenthal et al., 2024 (Systematic Review)

Tier 2: Strong Evidence, Some Off-Label or Non-FDA Uses

3. Oral Dutasteride (0.5 mg/day)

• Inhibits both Type I and II 5α-reductase (finasteride only inhibits Type II), so it is a stronger DHT suppressor.
• More effective than finasteride with a comparable safety profile.
• FDA-approved for benign prostatic hyperplasia; approved for AGA in South Korea and Japan; used off-label in many countries.
• A systematic review (141 studies) confirmed its superiority over finasteride for hair counts.
• Goldman-Cecil Medicine, p. 4334 | Rosenthal et al., 2024

4. Low-Dose Oral Minoxidil (0.25 - 2.5 mg/day)

• A major trend supported by robust data. Doses far lower than the antihypertensive dose (10-40 mg) are effective.
• Works systemically to stimulate hair growth; multiple studies confirm safety and efficacy in both men and women.
• Men: 2.5 mg/day; Women: 0.625-1.25 mg/day (lower doses to reduce hypertrichosis risk)
• Side effects: unwanted facial hair (most common), ankle edema, headache, rare cardiovascular effects.
• Convenient (once-daily pill vs. twice-daily topical) - improving adherence.
• Dermatology 2-Volume Set 5e | Goldman-Cecil Medicine, p. 4334

5. JAK Inhibitors for Alopecia Areata

• Baricitinib (Olumiant) - FDA-approved 2022 for severe AA
• Ritlecitinib (Litfulo) - FDA-approved 2023 for severe AA (approved for ages 12+)
• Mechanism: Block JAK/STAT pathway, which drives the autoimmune T-cell attack on hair follicles.
• A 2023 Cochrane network meta-analysis (63 RCTs, 4,817 participants) found JAK inhibitors showed the most promising data for significant hair regrowth in AA compared to other therapies.
• A 2025 indirect comparison systematic review confirmed both ritlecitinib and baricitinib are effective, with ritlecitinib having a broader age indication.

Tier 3: Procedural Treatments - Good Supporting Evidence

6. Hair Transplantation (FUE / FUT)

• Gold standard surgical option for androgenetic alopecia with adequate donor hair.
• Follicular Unit Extraction (FUE) and strip harvesting (FUT) both produce natural-appearing results.
• Based on the principle of donor dominance - transplanted hairs retain their donor-site genetic characteristics and resist DHT.
• Combining finasteride 1 mg/day with transplantation produces significantly greater hair counts at 48 weeks post-surgery vs. transplantation alone.
• Best for men with stabilized, moderate-to-severe AGA; more complex in women due to diffuse thinning pattern.
• Cummings Otolaryngology, p. 1963-1975

7. Microneedling (with Minoxidil)

• A 2025 meta-analysis of 12 RCTs (631 patients) found that combined microneedling + minoxidil significantly outperformed minoxidil alone for hair count (SMD 1.32, p<0.01) and hair diameter (SMD 0.34).
• Microneedling creates microchannels that enhance minoxidil absorption, and may directly stimulate follicles via mechanical activation of Wnt/β-catenin signaling.
• Needle depth, device type, and session duration did not significantly affect outcomes.
• Adverse events (erythema, mild pain) are mild and self-limiting.
• Practical use: Roller or pen device, 0.5-1.5mm depth, combined with topical minoxidil at the same session.

8. Low-Level Laser/LED Therapy (LLLT)

• A 2025 systematic review and meta-analysis (38 studies, 3,098 patients) found LLLT significantly increased hair density in AGA compared to placebo at both <20 weeks (SMD 1.14) and >20 weeks (SMD 1.44).
• Wavelengths of 630-680 nm are used in FDA-cleared home devices (e.g., HairMax laser combs/caps, iRestore).
• Mechanism: photons absorbed by cytochrome oxidase in mitochondria → increased ATP production → reduced follicular apoptosis → prolonged anagen phase.
• Safe, no systemic side effects. Optimal frequency and duration still being refined.
• Evidence for non-AGA alopecias (AA, scarring) is insufficient for meta-analysis.

9. Platelet-Rich Plasma (PRP)

• Autologous blood is centrifuged to concentrate platelets, then injected into the scalp.
• Growth factors released (PDGF, TGF-β, VEGF, EGF, IGF) are thought to stimulate follicular regeneration.
• Systematic review evidence (2024) shows hair growth benefit, but results are mixed and protocols vary widely (concentration, frequency, activation method).
• Generally used as an adjunct - particularly alongside hair transplantation to improve graft survival and density.
• No large standardized RCTs yet; evidence quality is moderate. Best considered a supplement to first-line treatments.
• Cummings Otolaryngology, p. 2153 | Dermatology 2-Volume Set 5e

Tier 4: Emerging Treatments (Phase 2-3 Data)

Treatment Summary by Type

Key Principles

1. Treatments must be continued indefinitely - stopping leads to return of hair loss within 3-12 months for most agents.
2. Allow 6-12 months before judging efficacy - the hair cycle is slow.
3. Combination therapy outperforms monotherapy - finasteride + minoxidil + microneedling is the most evidence-backed combination for AGA.
4. Individualize based on sex, age, type of alopecia, comorbidities, and side-effect tolerance.